VALIANTLABNSEValiant Laboratories LimitedHighNeutral
Announced Tue, 11 Nov, 2025 · 17:08 IST

Q2 FY26 results: revenue more than doubles, PAT turns positive

Revenue Growth 20pctPat Growth 25pctResults View source PDFExplain this filing

VALIANTLAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-3.0%Reaction day
₹82.95
prior close
₹80.45
announcement price
After-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used+0.9%-3.9% vs market

On the reaction day the stock moved 3.9 pts less than Nifty Microcap 250, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+0.8
10m
+1.5
15m
+1.6
30m
+1.3
Sessions after the filingfrom the prior close
StockMarketvs market
Reaction day
-3.0+0.9-3.9
Next day
-4.2+0.8-5.0
2d
-4.7+0.7-5.4
3d
-2.7+1.3-4.1
4d
-4.4+0.5-5.0
5d
-6.9+0.4-7.3
1w
-12.1-1.5-10.6
15d
-21.9-2.4-19.5
1m
-19.2-4.4-14.8
2m
-21.3-7.2-14.1
3m
-24.7-5.0-19.7
UpDownMarket · Nifty Microcap 250Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Board approved audited Q2 and H1 FY26 results ending Sep 30, 2025. Standalone revenue from operations jumped to Rs 9,699.49 lakhs in H1 from Rs 4,036.33 lakhs a year ago. Q2 revenue rose to Rs 4,595.77 lakhs from Rs 2,147.90 lakhs. Net profit turned positive at Rs 16.67 lakhs (standalone Q2) and Rs 196.24 lakhs (standalone H1) versus losses last year. Consolidated H1 revenue grew to Rs 9,302.52 lakhs with PAT of Rs 272.52 lakhs. Auditor issued unqualified opinion.

Likely market impact

Sharp revenue growth and return to profitability signal business recovery, likely positive for stock sentiment.